Dysfunction of the Blood Brain Barrier (BBB) has been shown in the brains of patients with Alzheimer's disease and other types of dementia. Vascular pathology and disturbance of the Blood Retinal Barrier (BRB) has been shown in living Alzheimer’s patients. There are no studies that quantify BBB/BRB pathologies in early stages of Alzheimer’s disease because of a lack of methods to perform this analysis.
Emagix provides an objective means of assessing BRB and BBB integrity in patients with Alzheimer's and other diseases. This evaluation also provides a means of assessing disease progression, and indicate the need for treatment, as well as evaluate the efficacy of a treatment.